Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Eitemau Tebyg

• Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
  gan: Chen, Yu-Mu, et al.
  Cyhoeddwyd: (2015)
• Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
  gan: Chang, Chia-Hao, et al.
  Cyhoeddwyd: (2015)
• Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
  gan: Chen, Yu-Mu, et al.
  Cyhoeddwyd: (2016)
• Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
  gan: Chen, Yu-Mu, et al.
  Cyhoeddwyd: (2016)
• The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
  gan: Chang, Shih-Chieh, et al.
  Cyhoeddwyd: (2011)